Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008955 | 0.78 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL3507933 | 0.71 | FDPS (0.38) | HDAC6HDAC1LTA4H | |
| SCHEMBL145694 | 0.71 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL25936242 | 0.68 | ADORA2A (0.38) | HDAC6HDAC1LTA4H | |
| SCHEMBL15645058 | 0.67 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL2010864 | 0.67 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL277148 | 0.67 | HDAC6 (0.46) | HDAC6HDAC1LTA4H | |
| SCHEMBL5803499 | 0.67 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL21357355 | 0.67 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL277149 | 0.67 | HDAC6 (0.43) | HDAC6HDAC1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670896-B1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2015-01-07 | — | — | EP | claimed |
| US-20090258931-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | claimed |
| EP-1670896-A4 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS INC (US) | 2009-03-04 | — | — | EP | claimed |
| EP-1670896-A2 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050074801-A1 | Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | claimed |
| WO-2005023995-A2 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-10900038-B2 | siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof | APPLIED BIOSYSTEMS, LLC (US) | 2021-01-26 | — | — | US | disclosed |
| US-10329564-B2 | siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof | APPLIED BIOSYSTEMS, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-10301626-B2 | Catalytic strands of minimal hammerhead ribozymes and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-28 | — | — | US | disclosed |
| US-10266825-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180080022-A1 | Catalytic Strands of Minimal Hammerhead Ribozymes and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-22 | — | — | US | disclosed |
| US-20050221275-A1 | Hepatocyte free uptake assays | ISIS PHARMACEUTICALS, INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050142581-A1 | Microrna as ligands and target molecules | ISIS PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050080246-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050074801-A1 | Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050026160-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2001025478-A1 | A METHOD OF INCREASING THE SPECIFICITY OF OXY-LNA OLIGONUCLEOTIDES | EXIQON A/S (DK) | 2001-04-12 | — | — | WO | disclosed |
| WO-1999011820-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND QUANTITATION OF DELETION SEQUENCE OLIGONUCLEOTIDES IN SYNTHETIC OLIGONUCLEOTIDE PREPARATIONS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258931-A1 | CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY | NSUN3, NSUN2, NOP2 | HDAC6 1298/4885HDAC1 1435/4885LTA4H 3499/4885 |
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | HDAC6 1506/4885HDAC1 1832/4885LTA4H 4465/4885 |
| US-20050080246-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | HDAC6 1554/4885HDAC1 1825/4885LTA4H 4477/4885 |
| US-20050074801-A1 | Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight | RNGTT, NSUN3, RNMT | HDAC6 2337/4885HDAC1 1245/4885LTA4H 2215/4885 |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | NSUN2, RNMT, NSUN3 | HDAC6 1554/4885HDAC1 1825/4885LTA4H 4477/4885 |
| US-20050026160-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | HDAC6 1554/4885HDAC1 1825/4885LTA4H 4477/4885 |
| US-10266825-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | HDAC6 1506/4885HDAC1 1832/4885LTA4H 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.